Clinical trial
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
NCT00035620 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00035620 |
|---|---|
| Title | Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy |
| Official title | A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Neutropenia |
| Intervention type | Drug |
| Interventions | pegfilgrastim, filgrastim |
| Enrollment | 44 |
| Start date | Apr 1, 2000 |
| Primary completion | Jan 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | May 6, 2002 |
| Last update posted | Feb 26, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: